Abstract

Growth hormone (GH) is a naturally occurring polypeptide hormone produced by somatotropic cells in the anterior pituitary. The main function of somatotropin is stimulation of linear growth, but it also affects carbohydrate metabolism, increases bone mass and has potent lipolytic, antinatriuretic and antidiuretic effects. Growth hormone deficiency (GHD) may occur both in children and in adults. At the moment there is no gold standard for the diagnosis of GHD, and the diagnosis should take into account clinical, auxological, biochemical and radiological changes and, if necessary, genetic testing. Recent studies have highlighted that the biochemical diagnosis of GH deficiency is still imperfect. Stimuli used in the tests are non-physiological, and various substances are characterized by a different mechanism of action and potency. A few years ago it was thought that GHD treatment in children must be completed at the end of linear growth. Studies performed in the last two decades have shown that GHD deficiency in adults may result in complex clinical problems, and if untreated shortens the life expectancy and worsens its comfort. Discontinuation of GH therapy after the final height has been reached in fact negatively impacts the physiological processes associated with the transition phase, which is the period of human life between achieving the final height and 25-30 years of age. Given the adverse metabolic effects of GH treatment interruption after linear growth has been completed, the latest recommendations propose reassessment of GH secretion in the period at least one month after cessation of treatment and continuation of the therapy in case of persistent deficit.

References

• 1. Alatzoglou K.S., Webb E.A., Le Tissier P., Dattani M.T.: Isolatedgrowth hormone deficiency (GHD) in childhood and adolescence:recent advances. Endocr. Rev., 2014; 35: 376-432
  Google Scholar
• 2. Amed S., Delvin E., Hamilton J.: Variation in growth hormone immunoassaysin clinical practice in Canada. Horm. Res., 2008; 69: 290-294
  Google Scholar
• 3. Aron D.C., Findling J.W., Blake Tyrrell J.: Podwzgórze i przysadka.W: Endokrynologia ogólna i kliniczna, red. Greeenspan F.S., GardnerD.G. Wydawnictwo Czelej, Lublin 2004, 109-176
  Google Scholar
• 4. Attanasio A.F., Shavrikova E.P., Blum W.F., Shalet S.: Quality oflife in childhood onset growth hormone-deficient patients in thetransition phase from childhood to adulthood. J. Clin. Endocrinol.Metab., 2005; 90: 4525-4529
  Google Scholar
• 5. Bang P., Bjerknes R., Dahlgren J., Dunkel L., Gustafsson J., JuulA., Kriström B., Tapanainen P., Aberg V.: A comparison of differentdefinitions of growth response in short prepubertal children treatedwith growth hormone. Horm. Res. Paediatr., 2011; 75: 335-345
  Google Scholar
• 6. Barake M., Klibanski A., Tritos N.A.: Effects of recombinant humangrowth hormone therapy on bone mineral density in adults withgrowth hormone deficiency: a meta-analysis. J. Clin. Endocrinol.Metab., 2014; 99: 852-860
  Google Scholar
• 7. Baroncelli G.I., Bertelloni S., Sodini F., Saggese G.: Acquisitionof bone mass in normal individuals and in patients with growthhormone deficiency. J. Pediatr. Endocrinol. Metab., 2003; 16 (Suppl.2): 327-335
  Google Scholar
• 8. Baumann G., Shaw M.A.: A second, lower affinity growth hormone-bindingprotein in human plasma. J. Clin. Endocrinol. Metab.,1990; 70: 680-686
  Google Scholar
• 9. Bex M., Abs R., Maiter D., Beckers A., Lamberigts G., Bouillon R.:The effects of growth hormone replacement therapy on bone metabolismin adult-onset growth hormone deficiency: a 2-year openrandomized controlled multicenter trial. J. Bone Miner. Res., 2002;17: 1081-1094
  Google Scholar
• 10. Binder G.: Growth hormone deficiency: new approaches to thediagnosis. Pediatr. Endocrinol. Rev., 2011; 9, Suppl. 1: 535-537
  Google Scholar
• 11. Bonfig W., Bechtold S., Bachmann S., Putzker S., Fuchs O., PagelP., Schwartz H.P.: Reassessment of the optimal growth hormonecut-off level in insulin tolerance testing for growth hormone secretionin patients with childhood-onset growth hormone deficiencyduring transition to adulthood. J. Pediatr. Endocrinol. Metab., 2008;21: 1049-1056
  Google Scholar
• 12. Boot A.M., van der Sluis I.M., Krenning E.P., de Muinck Keizer–Schrama S.M.: Bone mineral density and body composition in adolescentswith childhood-onset growth hormone deficiency. Horm.Res., 2009; 71: 364-371
  Google Scholar
• 13. Capaldo B., Guardasole V., Pardo F., Matarazzo M., Di Rella F.,Numis F., Merola B., Longobardi S., Sacca L.: Abnormal vascular reactivityin growth hormone deficiency. Circulation, 2001; 103: 520-524
  Google Scholar
• 14. Capaldo B., Patti L., Oliviero U., Longobardi S., Pardo F., VitaleF., Fazio S., Di Rella F., Biondi B., Lombardi G. Sacca L.: Increased arterialintima-media thickness in childhood-onset growth hormonedeficiency. J. Clin. Endocrinol. Metab., 1997; 82: 1378-1381
  Google Scholar
• 15. Chaves V.E., Júnior F.M., Bertolini G.L.: The metabolic effectsof growth hormone in adipose tissue. Endocrine, 2013; 44: 293-302
  Google Scholar
• 16. Cianfarani S., Tondinelli T., Spadoni G.L., Scirè G., Boemi S., BoscheriniB.: Height velocity and IGF-I assessment in the diagnosisof childhood onset GH insufficiency: do we still need a second GHstimulation test? Clin. Endocrinol., 2002; 57: 161-167
  Google Scholar
• 17. Clayton P.E., Cuneo R.C., Juul A., Monson J.P., Shalet S.M., TauberM.: Consensus statement on the management of the GH-treatedadolescent in the transition to adult care. Eur. J. Endocrinol., 2005;152: 165-170
  Google Scholar
• 18. Colao A.: The GH-IGF-I axis and the cardiovascular system: clinicalimplications. Clin. Endocrinol., 2008; 69: 347-358
  Google Scholar
• 19. Colao A., Cerbone G., Pivonello R., Aimaretti G., Loche S., DiSomma C., Faggiano A., Corneli G., Ghigo E., Lombardi G.: The growthhormone (GH) response to the arginine plus GH-releasing hormonetest is correlated to the severity of lipid profile abnormalities inadult patients with GH deficiency. J. Clin. Endocrinol. Metab., 1999;84: 1277-1282
  Google Scholar
• 20. Colao A., Di Somma C., Cuocolo A. Filippella M., Rota F., AcampaW., Savastano S., Salvatore M., Lombardi G.: The severity of growthhormone deficiency correlates with the severity of cardiac impairmentin 100 adult patients with hypopituitarism: an observational,case-control study. J. Clin. Endocrinol. Metab., 2004; 89: 5998-6004
  Google Scholar
• 21. Colao A., Di Somma C., Pivonello R., Loche S., Aimaretti G., CerboneG., Faggiano A., Corneli G., Ghigo E., Lombardi G.: Bone loss iscorrelated to the severity of growth hormone deficiency in adultpatients with hypopituitarism. J. Clin. Endocrinol. Metab., 1999;84: 1919-1924
  Google Scholar
• 22. Colao A., Di Somma C., Rota F., Di Maio S., Salerno M., Klain A.Spiezia S., Lombardi G.: Common carotid intima-media thickness ingrowth hormone (GH)-deficient adolescents: a prospective studyafter GH withdrawal and restarting GH replacement. J. Clin. Endocrinol.Metab., 2005; 90: 2659-2665
  Google Scholar
• 23. Colao A., Di Somma C, Salerno M, Spinelli L, Orio F, LombardiG.: The cardiovascular risk of GH-deficient adolescents. J. Clin. Endocrinol.Metab., 2002; 87: 3650-3655
  Google Scholar
• 24. Colle M., Auzerie J.: Discontinuation of growth hormone therapyin growth-hormone deficient patients: assessment of body fatmass using bioelectrical impedance. Horm. Res., 1993; 39: 192-196
  Google Scholar
• 25. Consensus Statement. Consensus guidelines for the diagnosisand treatment of adults with growth hormone deficiency: summarystatement of the Growth Hormone Research Society Workshopon adult growth hormone deficiency. J. Clin. Endocrinol. Metab.,1998; 83: 379-381
  Google Scholar
• 26. Conway G.S., Szarras-Czapnik M., Racz K., Keller A., ChansonP., Tauber M., Zacharin M. and on behalf of the 1369 GHD to GHDATransition Study Group: Treatment for 24 months with recombinanthuman GH has a beneficial effect on bone mineral density inyoung adults with childhood-onset GH deficiency. Eur. J. Endocrinol.,2009; 160: 899-907
  Google Scholar
• 27. Cook D.M., Rose S.R.: A review of guidelines for use of growthhormone in pediatric and transition patients. Pituitary, 2012; 15:301-310
  Google Scholar
• 28. Cook D.M., Yuen K.C., Biller B.M., Kemp S.F., Vance M.L., AmericanAssociation of Clinical Endocrinologists: American Associationof Clinical Endocrinologists medical guidelines for clinicalpractice for growth hormone use in growth hormone-deficientadults and transition patients – 2009 update. Endocr. Pract., 2009; 15 (Suppl. 2): 1-29
  Google Scholar
• 29. Corneli G., Di Somma C., Prodam F., Bellone J. Bellone S., GascoV., Baldelli R., Rovere S., Schneider H.J., Gargantini L., Gastaldi R.,Ghizzoni L., Valle D., Salerno M., Colao A., Bona G., Ghigo E., MaghnieM., Aimaretti S.: Cut-off limits of the GH response to GHRH plus argininetest and IGF-I levels for the diagnosis of GH deficiency in lateadolescents and young adults. Eur. J. Endocrinol., 2007: 157: 701-708
  Google Scholar
• 30. Cunningham B.C., Ultsch M., De Vos A.M., Mulkerrin M.G., ClauserK.R., Wells J.A.: Dimerization of the extracellular domain of thehuman growth hormone receptor by a single hormone molecule.Science, 1991; 254: 821-825
  Google Scholar
• 31. de Boer H., Blok G.J., Voerman B., Derriks P., van der Veen E.:Changes in subcutaneous and visceral fat mass during growth hormonetherapy in adult men. Int. J. Obes. Relat. Metab. Disord., 1996;20: 580-587
  Google Scholar
• 32. De Vriese C., Delporte C.: Ghrelin: a new peptide regulatinggrowth hormone release and food intake. Int. J. Biochem. Cell Biol.,2008; 40: 1420-1424
  Google Scholar
• 33. Dimke H., Flyvbjerg A., Frische S.: Acute and chronic effects ofgrowth hormone on renal regulation of electrolyte and water homeostasis.Growth Horm. IGF Res., 2007; 17: 353-368
  Google Scholar
• 34. Drake W.M., Howell S.J., Monson J.P., Shalet S.M.: OptimizingGH therapy in adults and children. Endocr. Rev., 2001; 22: 425-450
  Google Scholar
• 35. Erfurth E.M.: Epidemiology of adult growth hormone deficiency.Prevalence, incidence, mortality and morbidity. Front. Horm.Res., 2005; 33: 21-32
  Google Scholar
• 36. Follin C., Thilen U., Ahren B., Erfurth E.M.: Improvement incardiac systolic function and reduced prevalence of metabolic syndromeafter two years of growth hormone (GH) treatment in GH–deficient adult survivors of childhood-onset acute lymphoblasticleukemia. J. Clin. Endocrinol. Metab., 2006; 91: 1872-1875
  Google Scholar
• 37. Gahete M.D., Duràn-Prado M., Luque R.M., Martinez-Fuentes A.J.,Quintero A., Gutierrez-Pascual E., Córdoba-Chacón J., Malagón M.M.,Garcia-Navarro F., Castaño J.P.: Understanding the multifactorialcontrol of growth hormone release by somatotropes. Lessons fromcomparative endocrinology. Ann. N.Y. Acad. Sci., 2009; 1163: 137-153
  Google Scholar
• 38. Gasco V., Corneli G., Beccuti G., Prodam F., Rovere S., BelloneJ., Grottoli S., Aimaretti G., Ghigo E.: Retesting the childhood-onsetGH-deficient patient. Eur. J. Endocrinol., 2008; 159, Suppl. 1: S45-S52
  Google Scholar
• 39. Gasco V., Prodam F., Grottoli S., Marzullo P., Longobardi S., GhigoE., Aimaretti G.: GH therapy in adult GH deficiency: a review of treatment schedules and the evidence for low starting doses. Eur. J.Endocrinol., 2013; 168: R55-R66
  Google Scholar
• 40. Gazzaruso C., Gola M., Karamouzis I., Giubbini R., Giustina A.:Cardiovascular risk in adult patients with growth hormone (GH)deficiency and following substitution with GH – an update. J. Clin.Endocrinol. Metab., 2014; 99: 18-29
  Google Scholar
• 41. GH Research Society: Consensus guideline for the diagnosisand treatment of growth hormone (GH) deficiency in childhoodand adolescence: summary statement of the GH Research Society.J. Clin. Endocrinol. Metab., 2000; 85: 3990-3993
  Google Scholar
• 42. Giustina A., Veldhuis J.D.: Pathophysiology of the neuroregulationof growth hormone secretion in experimental animals and thehuman. Endocrine Rev., 1998; 19: 717-797
  Google Scholar
• 43. Giustina A., Wehrenberg W.B.: The role of glucocorticoids inthe regulation of growth hormone secretion. Trends Endocrinol.Metab., 1992; 3: 306-311
  Google Scholar
• 44. Goldenberg N., Barkan A.: Factors regulating growth hormonesecretion in humans. Endocrinol. Metab. Clin. North Am., 2007;36: 37-55
  Google Scholar
• 45. Hilczer M., Lewiński A.: Wskazania do leczenia hormonem wzrostuu dzieci i dorosłych. Przegl. Pediatr., 2004; 34: 170-175
  Google Scholar
• 46. Hilczer M., Smyczyńska J., Stawerska R., Lewiński A.: Effects ofone-year low-dose growth hormone (GH) therapy on body composition,lipid profile and carbohydrate metabolism in young adults withchildhood-onset severe GH deficiency confirmed after completionof growth promotion. Endokrynol. Pol., 2008; 59: 292-300
  Google Scholar
• 47. Ho K.K. on behalf of the 2007 GH Deficiency Consensus WorkshopParticipants: Consensus guidelines for the diagnosis and treatmentof adults with GH deficiency II: a statement of the Research Societyin association with the European Society for Pediatric Endocrinology,Lawson Wilkins Society, European Society of Endocrinology,Japan Endocrine Society, and Endocrine Society of Australia. Eur. J.Endocrinol., 2007; 157: 695-700
  Google Scholar
• 48. Høybye C., Cohen P., Hoffman A.R., Ross R., Biller B.M., ChristiansenJ.S., Growth Hormone Research Society: Status of long-acting-growthhormone preparations – 2015. Growth Horm. IGF Res.,2015; 25: 201-206
  Google Scholar
• 49. Hulthen L., Bengtsson B.A., Stibrant Sunnerhagen S., HallbergL. Grimby G., Johannsson G.: GH is needed for maturation of musclemass and strength in adolescents. J. Clin. Endocrinol. Metab., 2001;86: 4765-4770
  Google Scholar
• 50. Itoh E., Hizuka N., Fukuda I., Takano K.: Metabolic disorders inadult growth hormone deficiency: a study of 110 patients at a singleinstitute in Japan. Endocr. J., 2006; 53: 539-545
  Google Scholar
• 51. Johannsson G., Albertsson-Wikland K., Bengtsson B.A.: Discontinuationof growth hormone (GH) treatment: metaboliceffects in GH-deficient and GH-sufficient adolescent patientscompared with control subjects. Swedish Study Group for GrowthHormone Treatment in Children. J. Clin. Endocrinol. Metab., 1999;84: 4516-4524
  Google Scholar
• 52. Jones J.I., Clemmons D.R.: Insulin-like growth factors and theirbinding proteins: biological actions. Endocr. Rev., 1995; 16: 3-34
  Google Scholar
• 53. Jǿrgensen J.O., Norrelund H, Vahl N., Juul A., Skakkebaek N.E.,Christiansen J.S.: Continuation of growth hormone therapy versusplacebo in transition-phase patients with growth hormone deficiency:impact on body composition, insulin sensitivity, and thyroidfunction. J. Pediatr. Endocrinol. Metab., 2002; 15 (Suppl. 5): 1355-1360
  Google Scholar
• 54. Józefiak A., Pacholska J. Kędzia W.: Rola IGF-I i IGFBP w procesieneogenezy. Perinatologia, Neonatologia i Ginekologia, 2008;1: 175-183
  Google Scholar
• 55. Koranyi J., Svensson J., Götherström G., Sunnerhagen K.S.,Bengtsson B.A., Johannsson G.: Baseline characteristics and the effectsof five years of GH replacement therapy in adults with GH deficiency of childhood or adulthood onset: a comparative, prospectivestudy. J. Clin. Endocrinol. Metab., 2001; 86: 4693-4699
  Google Scholar
• 56. Lanes R., Marcano H., Villaroel O., Gunczler P., Morillo E., PaoliM., Perez M., Maulino N., Palacios A.: Circulating levels of high-sensitivityC-reactive protein and soluble markers of vascular endothelialcell activation in growth hormone-deficient adolescents. Horm.Res., 2008; 70: 230-235
  Google Scholar
• 57. Lanes R., Paoli M., Carrillo E., Villaroel O., Palacios A.: Peripheralinflammatory and fibrinolytic markers in adolescents with growthhormone deficiency: relation to postprandial dyslipidemia. J. Pediatr.,2004; 145: 657-661
  Google Scholar
• 58. Leczenie niskorosłych dzieci z somatropinową niedoczynnościąprzysadki (ICD10 E23) hormonem wzrostu. Obwieszczenie MinistraZdrowia z dnia 26 sierpnia 2015 r. w sprawie wykazu refundowanychleków, środków spożywczych specjalnego przeznaczeniażywieniowego oraz wyrobów medycznych. Dz. Urz. Min. Zdrow.,2015; 42: zał. B.19
  Google Scholar
• 59. Leong G.M., Johannsson G.: Growth hormone deficiency: strategiesand indications to continue growth hormone therapy in transitionfrom adolescence to adult life. Horm. Res., 2003; 60 (Suppl.1): 78-85
  Google Scholar
• 60. Maghnie M., Aimaretti G., Bellone S., Bona G., Bellone J., BaldelliR., de Sanctis C., Gargantini L., Gastaldi R., Ghizzoni L., Secco A., TinelliC., Ghigo E.: Diagnosis of GH deficiency in the transition period:accuracy of insulin tolerance test and insulin-like growth factor-Imeasurement. Eur. J. Endocrinol., 2005; 152: 589-596
  Google Scholar
• 61. Molitch M.E., Clemmons D.R., Malozowski S., Merriam G.R.,Vance M.L., Endocrine Society: Evaluation and treatment of adultgrowth hormone deficiency: an Endocrine Society clinical practiceguideline. J. Clin. Endocrinol. Metab. 2011; 96: 1587-1609 62 Møller N., Jørgensen J.O.: Effects of growth hormone on glucose,lipid, and protein metabolism in human subjects. Endocr. Rev.,2009; 30: 152-177
  Google Scholar
• 62. (Suppl. 3): 35-41
  Google Scholar
• 63. Monzavi R., Cohen P.: IGFs and IGFBPS: role in health and disease.Best Pract. Res. Clin. Endocrinol Metab., 2002; 16: 433-447
  Google Scholar
• 64. Morrison C.D.: Leptin signaling in brain: a link between nutritionand cognition? Biochim. Biophys. Acta, 2009; 1792: 401-408
  Google Scholar
• 65. Mukherjee A., Murray R.D., Shalet S.: Impact of growth hormonestatus on body composition and the skeleton. Horm. Res., 2004;
  Google Scholar
• 66. Murray P.G., Dattani M.T., Clayton P.E.: Controversies in the diagnosisand management of growth hormone deficiency in childhoodand adolescence. Arch. Dis. Child., 2016; 101: 96-100
  Google Scholar
• 67. Murray R.D., Adams J.E., Shalet S.M.: Adults with partial growthhormone deficiency have an adverse body composition. J. Clin. Endocrinol.Metab., 2004; 89: 1586-1591
  Google Scholar
• 68. Oswiecimska J.M., Roczniak W., Romanowicz D., Szymlak A.,Mikolajczak A., Malczyk Z., Stojewska M., Ziora K.T.: Quality of lifein transition phase in adolescents and young adults with severeand partial growth hormone deficiency. Neuro Endocrinol. Lett.,2014; 35: 676-683
  Google Scholar
• 69. Pouliot M.C., Després J.P., Lemieux S., Moorjani S., BouchardC., Tremblay A., Nadeau A., Lupien P.J.: Waist circumference andabdominal sagittal diameter: best simple anthropometric indexesof abdominal visceral adipose tissue accumulation andrelated cardiovascular risk in men and women. Am. J. Cardiol.,1994; 73: 460-468
  Google Scholar
• 70. Radovick S., DiVall S.: Approach to the growth hormone-deficientchild during transition to adulthood. J. Clin. Endocrinol. Metab.,2007; 92: 1195-1200
  Google Scholar
• 71. Richmond E.J., Rogol A.D.: Growth hormone deficiency in children.Pituitary, 2008; 11: 115-120
  Google Scholar
• 72. Rosenfeld R.G., Nicodemus B.C.: The transition from adolescenceto adult life: physiology of the “transition” phase and its evolutionarybasis. Horm. Res., 2003; 60 (Suppl. 1): 74-77
  Google Scholar
• 73. Rutherford O.M., Jones D.A., Round J.M., Buchanan C.R., PreeceM.A.: Changes in skeletal muscle and body composition afterdiscontinuation of growth hormone treatment in growth hormonedeficient young adults. Clin. Endocrinol., 1991; 34: 469-475
  Google Scholar
• 74. Sartorio A., Ferrero S., Conti A., Bragato R., Malfatto G., LeonettiS., Faglia G.: Adults with childhood-onset growth hormone deficiency:effects of growth hormone treatment on cardiac structure. J. Int.Med., 1997; 241: 515-520
  Google Scholar
• 75. Shalet S.M., Shavrikova E., Cromer M., Child C.J., Keller E., ZapletalovaJ., Moshang T., Blum W.F., Chipman J.J., Quigley C.A., AttanasioA.F.: Effect of growth hormone (GH) treatment on bone inpostpubertal GH-deficient patients: a 2-year randomized, controlled,dose-ranging study. J. Clin. Endocrinol. Metab., 2003; 88: 4124-4129
  Google Scholar
• 76. Shibasaki T., Hotta M., Masuda A., Imaki T., Obara N., DemuraH., Ling N., Shizume K.: Plasma GH responses to GHRH and insulin–induced hypoglycemia in man. J. Clin. Endocrinol. Metab., 1985;60: 1265-1267
  Google Scholar
• 77. Sizonenko P., Clayton P.E., Cohen P., Hintz R.L., Tanaka T., LaronZ.: Diagnosis and management of growth hormone deficiencyin childhood and adolescence. Part 1: Diagnosis of growth hormonedeficiency. Growth Horm. IGF Res., 2001; 11: 137-165
  Google Scholar
• 78. Stanley T.: Diagnosis of growth hormone deficiency in childhood.Curr. Opin. Endocrinol. Diabetes Obes., 2012; 19: 47-52
  Google Scholar
• 79. Tanaka T., Tachibana K., Shimatsu A., Katsumata N., TsushimaT., Hizuka N., Fujieda K., Yokoya S., Irie M.: A nationwide attempt tostandardize growth hormone assays. Horm. Res., 2005; 64 (Suppl.2): 6-11
  Google Scholar
• 80. Taubert M., Jouret B., Cartault A., Lounis N., Gayrard M., MarcouyeuxC., Pienkowski C., Oliver J., Moulin P. Otal P. Joffre F., AranuD. C., Rochiccioli P.: Adolescents with partial growth hormone(GH) deficiency develop alterations of body composition after GHdiscontinuation and require follow-up. J. Clin. Endocrinol. Metab.,2003; 88: 5101-5106
  Google Scholar
• 81. Veldhuis J.D.: Neuroendocrine control of pulsatile growth hormonerelease in human: relationship with gender. Growth Horm.IGF Res., 1998; 8, Suppl. B: 49-59
  Google Scholar
• 82. Walczak M., Romer T.E., Korman E., Małecka-Tendera E., Lewiń-ski A., Rymkiewicz-Kluczyńska B., Szewczyk L., Urban M., Roszkowska-BlaimM., Niedziela M., Noczyńska A., Starzyk J., Szalecki M.,Dorant B., Ginalska-Malinowska M. i wsp.: Zasady postępowania wprzypadku niskorosłości uwarunkowanej somatotropinową niedoczynnościąprzysadki. Klin. Pediatr., 2005; 13: 212-221
  Google Scholar
• 83. Wang G., Anini Y., Wei W., Qi X., O’Carroll A.M., Mochizuki T,Wang H.Q., Hellmich M.R., Englander E.W., Greeley G.H. Jr.: Apelin,a new enteric peptide: localization in the gastrointestinal tract, ontogenyand stimulation of gastric cell proliferation and of cholecystokininsecretion. Endocrinology, 2004; 145: 1342-1348
  Google Scholar

Full text